The novel PI3K inhibitor S1 synergizes with sorafenib in non-small cell lung cancer cells involving the Akt-S6 signaling
出版年份 2018 全文链接
标题
The novel PI3K inhibitor S1 synergizes with sorafenib in non-small cell lung cancer cells involving the Akt-S6 signaling
作者
关键词
-
出版物
INVESTIGATIONAL NEW DRUGS
Volume -, Issue -, Pages -
出版商
Springer Nature America, Inc
发表日期
2018-11-19
DOI
10.1007/s10637-018-0698-2
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Lung cancer: current therapies and new targeted treatments
- (2017) Fred R Hirsch et al. LANCET
- Global cancer statistics, 2012
- (2015) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Monotherapy Administration of Sorafenib in Patients With Non–Small Cell Lung Cancer (MISSION) Trial
- (2015) Luis Paz-Ares et al. Journal of Thoracic Oncology
- Discovery of 2-methoxy-3-phenylsulfonamino-5-(quinazolin-6-yl or quinolin-6-yl)benzamides as novel PI3K inhibitors and anticancer agents by bioisostere
- (2014) Teng Shao et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Combine MEK inhibition with PI3K/mTOR inhibition exert inhibitory tumor growth effect on KRAS and PIK3CA mutation CRC xenografts due to reduced expression of VEGF and matrix metallopeptidase-9
- (2014) Jifu E et al. TUMOR BIOLOGY
- Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC
- (2013) Susan Heavey et al. CANCER TREATMENT REVIEWS
- Preclinical Rationale for PI3K/Akt/mTOR Pathway Inhibitors as Therapy for Epidermal Growth Factor Receptor Inhibitor-Resistant Non–Small-Cell Lung Cancer
- (2013) Shirish M. Gadgeel et al. Clinical Lung Cancer
- Targeted therapy for non-small-cell lung cancer: past, present and future
- (2013) Patrick M Forde et al. Expert Review of Anticancer Therapy
- RAS/RAF/MEK Inhibitors in Oncology
- (2012) M. Broggini CURRENT MEDICINAL CHEMISTRY
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- The Combination of RAD001 and NVP-BEZ235 Exerts Synergistic Anticancer Activity against Non-Small Cell Lung Cancer In Vitro and In Vivo
- (2011) Cheng-Xiong Xu et al. PLoS One
- The BATTLE Trial: Personalizing Therapy for Lung Cancer
- (2011) Edward S. Kim et al. Cancer Discovery
- Sorafenib in Lung Cancer: Clinical Developments and Future Directions
- (2010) George Blumenschein Journal of Thoracic Oncology
- Prognostic Value of Vascular Endothelial Growth Factor Expression in Patients with Lung Cancer: A Systematic Review with Meta-Analysis
- (2010) Ping Zhan et al. Journal of Thoracic Oncology
- Sorafenib in Patients with Advanced Non-small Cell Lung Cancer that Harbor K-Ras Mutations: A Brief Report
- (2010) Egbert F. Smit et al. Journal of Thoracic Oncology
- Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin
- (2010) Steven D. Knight et al. ACS Medicinal Chemistry Letters
- Lung cancer therapeutics that target signaling pathways: an update
- (2010) M Roshni Ray et al. Expert Review of Respiratory Medicine
- Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo
- (2009) Pippa Newell et al. JOURNAL OF HEPATOLOGY
- Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer
- (2008) Arkaitz Carracedo et al. JOURNAL OF CLINICAL INVESTIGATION
- Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
- (2008) S.-M. Maira et al. MOLECULAR CANCER THERAPEUTICS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started